Sloveenia - sloveeni - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - eptifibatid - raztopina za infundiranje - eptifibatid 2 mg / 1 ml - eptifibatid

Sloveenia - sloveeni - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - eptifibatid - raztopina za infundiranje - eptifibatid 0,75 mg / 1 ml - eptifibatid

Euroopa Liit - sloveeni - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - bimatoprost, timolol - glaucoma, open-angle; ocular hypertension - oftalmologi - zmanjšanje intraokularnega tlaka (iop) pri bolnikih z glavkomom odprtega zakotja ali očesno hipertenzijo, ki se premalo odzivajo na topične beta blokatorje ali analoge prostaglandinov.

Euroopa Liit - sloveeni - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - bimatoprost - glaucoma, open-angle; ocular hypertension - prostaglandin analogues, ophthalmologicals - zmanjšanje zvišanega očesnega tlaka pri kroničnem glavkomu odprtega zakotja in očesni hipertenziji (kot monoterapija ali kot dodatno zdravljenje zaviralcev beta).

Euroopa Liit - sloveeni - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.

Euroopa Liit - sloveeni - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - zavrnitev presadka - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Euroopa Liit - sloveeni - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolakton - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 in 5.

Euroopa Liit - sloveeni - EMA (European Medicines Agency)

novartis europharm limited - nilotinib - levkemija, mielogena, kronična, bcr-abl pozitivna - antineoplastična sredstva - tasigna je primerna za zdravljenje:izobraževanje odraslih in pediatričnih bolnikih, ki so na novo zboleli za philadelphia kromosom pozitivno kronične myelogenous levkemijo (cml) v kronično fazo,pediatričnih bolnikih s philadelphia kromosom pozitivno cml v kronični fazi pa z odpornost ali nestrpnosti predhodno zdravljenje, vključno z imatinib. tasigna je primerna za zdravljenje:izobraževanje odraslih in pediatričnih bolnikih, ki so na novo zboleli za philadelphia kromosom pozitivno kronične myelogenous levkemijo (cml) v kronično fazo,odraslih bolnikih s kronično fazo in pospešeni fazi philadelphia kromosom pozitivno cml s odpornost ali nestrpnosti predhodno zdravljenje, vključno z imatinib. podatki o učinkovitosti pri bolnikih s cml v blastni krizi niso na voljo,pediatričnih bolnikih s kronično fazo philadelphia kromosom pozitivno cml s odpornost ali nestrpnosti predhodno zdravljenje, vključno z imatinib.

Sloveenia - sloveeni - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

arrow generics limited - lerkanidipin - filmsko obložena tableta - lerkanidipin 18,8 mg / 1 tableta - lerkanidipin

Sloveenia - sloveeni - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

arrow generics limited - lerkanidipin - filmsko obložena tableta - lerkanidipin 9,4 mg / 1 tableta - lerkanidipin